ClinicalTrials.gg
RecruitingNCT07004192Updated Jul 1, 2025

The Role of hCG in Thawed Embryo Transfer

A Phase 4 interventional study of HCG injection and No intervention in Infertility (IVF Patients), sponsored by Fertility Center of Las Vegas. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Fertility Center of Las Vegas · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies testing Chorionic Gonadotropin in Infertility — 4 open to participants now, 4 under way, 2 of them phase 3. Chorionic Gonadotropin · Infertility.

Planned enrollment
12th of 40
220 · median 135
Started
2025
the only one that year
Phase 4
18 of 40
1 open now
Registered
39th of 40
by date

Among the 40 studies testing Chorionic Gonadotropin in Infertility, this one is the 12th largest by planned enrollment, is the only one that started in 2025, is one of 18 in phase 4, and was the 39th registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 356 are open to participants now.

Browse Infertility studies →

Open to participants now

4 of the 40 studies testing Chorionic Gonadotropin in Infertility are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Chorionic Gonadotropin

Chorionic Gonadotropin: first FDA approval 1973 (CHORIONIC GONADOTROPIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 234 Infertility studies recruiting now, 43 (18%) set no upper age limit and 185 (79%) stop at 75 or younger; 27 take children under 18; 76 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing Chorionic Gonadotropin in Infertility, or all of them as a file.
02

Study summary

This prospective randomized trial will assess the relevance, if any, of a corpus luteum induced by hCG in transfers of thawed embryos.

Read the detailed description

The current study is designed to carefully isolate the effect of a corpus luteum by ensuring that the presence or absence of a corpus luteum is the only difference between two study arms. This should be reliably achieved by administering an injection of hCG in one study arm, while the other study arm has identical treatment except for omitting the hCG.

03

Conditions studied

  • Infertility (IVF Patients)

Browse trials for

Keywords

  • Thawed embryo transfer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female adult expecting to receive transfer of a thawed embryo.
  2. At least one available frozen blastocyst of transferrable quality.
  3. Non-menopausal female with at least one antral follicle.
  4. Use of pre-implantation genetic testing (PGT), embryos derived from donor oocytes and/or donor sperm, a gestational carrier, and history of prior transfer(s) regardless of outcome are allowed.
  5. Subsequent embryo transfers after failed transfers under this study are allowed, but not after a transfer that has resulted in ongoing pregnancy at ten weeks gestation under this study.

Exclusion criteria

Exclusion Criteria:

  1. Minors (age\<18 years).
  2. Use of embryo(s) frozen at another center.
  3. Patient insistent on transfer of two embryos.
  4. Patient or partner unable to provide in English.
  5. Patient already enrolled in any other research study for her embryo transfer.
  6. History of anti-phospholipid syndrome or any other indication for use of Lovenox in pregnancy.
  7. Patient for whom the physician assesses this protocol is inappropriate or unsafe.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    hCG Group

    This group receives one injection of hCG.

    Drug: HCG injection

  • Active comparator
    No hCG Group

    This arm receives no hCG.

    Other: No intervention

Interventions

  • 5000 IU hCG injection

  • OtherNo intervention

    No hCG administered in this group.

06

What researchers measure

Primary outcomes

  1. Blood pressure

    Mean arterial pressure measured in third trimester of pregnancy

    Time frame: Third trimester of pregnancy

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No current plan to do so in approved protocol.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.

Of 81 phase 4 interventional studies under Infertility, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 82. This study's planned 30 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jun 4, 2025
StartActual
Jun 2, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07004192
Lead sponsor
Fertility Center of Las Vegas
Responsible party
Bruce Shapiro M.D. (Medical Director, Fertility Center of Las Vegas) — Principal investigator
First posted
Jun 4, 2025
Start date
Jun 2, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 1, 2025

Study contacts

Shironda Research Assistant
Contact
shironda@fertilitycenterlv.com
702-254-1777 ext. 265

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chorionic Gonadotropin

Start the discussion